Skip to main content

Breakthrough Obesity Drugs

 


Breakthrough Obesity Drugs. Could dieting become obsolete?
Carlos Martinez Sagasta

In the past 50 years, the prevalence of obesity has tripled. Being significantly overweight increases the chances of developing various health issues like type 2 diabetes, heart disease, and several malignancies.

The need for the creation of efficient obesity treatments is growing as obesity rates rise.

New hormone-mimicking pharmaceuticals may reduce hunger and encourage weight loss regarding the advancement and possibility of novel treatments for obesity.

It may reduce the cause of experiencing emotions of guilt and the stigma associated with being overweight.

GLP-1 receptor agonists, which have been biochemically designed to increase potency and have a sustained effect, are successfully used in clinical settings to treat type-2 diabetes.

The GLP-1 analogue Semaglutide was initially licensed by the US FDA to treat type 2 diabetes, but was later approved as a medication to treat obesity.

In a trial, semaglutide users dropped an average of roughly 16% of body weight, more than twice as much as those on an earlier weight-loss medication.

Other potent anti-obesity drugs are currently being researched and developed, including tirzepatide and retatrutide.

How do these drugs work?


The complex hormone glucagon-like peptide-1 (GLP-1) has a wide range of therapeutic applications, as shown both in humans and animals:
  • Glucose-dependent stimulation of insulin secretion
  • Delaying of stomach emptying
  • Suppression of food intake
  • Alleviation of spatial memory dysfunction and learning
  • Potential target for psychostimulant abuse
  • Cardio- and neuroprotective effects
  • Reduces inflammation and apoptosis (a form of programmed cell death)
These mechanisms of action, as well as how they affect appetite control and weight loss, are still being studied.

These medications are thought to function by simulating hormones that suppress the appetite and induce feelings of fullness, which lower the amount of food consumed.

In patients with Inflammatory Bowel Disease (IBD) and type 2 diabetes, a lower risk of adverse clinical events was observed amongst patients treated with GLP-1 based therapies.

These findings suggest that treatment with GLP-1 based therapies may improve the disease course of IBD.

A recent study showed that semaglutide treatment resulted in a 20% decrease of major adverse cardiovascular events over a period of up to five years. These events included cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.

GLP-1 receptor agonists are effective and tolerable for antipsychotic-associated body weight gain. The use of these medications for psychiatry patients has grown so much that some physicians are considering drafting a standard approach paper for the staff on prescribing them.

Despite the positive clinical trial outcomes, not everyone responds to the medications in the same way. How each person reacts can vary depending on their genetics, lifestyle, and starting weight.

These drugs’ long-term effects and safety are still being studied.

Short-term adverse effects like nausea and vomiting have been noted in certain cases. Most reported side effects were:Nausea (44%)
  • Diarrhea (30%)
  • Vomiting (24%)
  • Constipation (24%)
  • Abdominal pain (20%)
  • Headache (14%)
  • Fatigue (11%)
Researchers are convinced that the treatments can be safe over long periods of time based on prior experience with similar pharmaceuticals used to treat type 2 diabetes, even though long-term usage may pose potential dangers.

Novo Nordisk, the manufacturer of semaglutide and liraglutide, remains confident in their benefit-risk profile and committed to patient safety despite reports of suicide or self-harm cases.

Social and economic perspectives


Based on existing data, it is unknown if glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, are cost-effective as therapies for obesity and type 2 diabetes.

Potential modifications in the future might boost their economic viability. Beyond reducing drug costs, a more thorough cost-analysis is needed, including treatment’s broader effects, such as pain, disability, depression, and societal expenses.

People who are physically active are less likely to become obese, regardless of how much they consume. For populations receiving appropriate nutrition, activity level is a more fundamental determinant of body weight than food is.

Patients who are stuck in a never-ending cycle of exercise and dieting seek something more practical with a more certain effect.

A practical substitute is a prescription for medication.

The enthusiasm among scientists and doctors for these new medications’ potential to treat obesity is clear, but there are also worries about potential side effects and societal repercussions.

Some fear that the availability of these drugs could exacerbate eating disorders. Then, promoting health awareness beyond weight should be emphasized.

Studies reveal the expanding research and interest in these novel obesity drugs, but it also raises concerns about individual reactions, long-term safety, and societal and economic repercussions.


Comments

Popular posts from this blog

Light Therapy holds promise as a treatment for Alzheimer's Disease

A new article, conducted by Lili Zang and colleagues from Weifang Medical University School of Nursing in Shandong Province, China, discusses a meta-analysis of 15 high-quality trials that investigated the impact of light therapy on individuals with Alzheimer’s disease (AD). The meta-analysis included 598 patients with mild to moderate Alzheimer’s disease, and it covered 15 randomized controlled trials conducted in seven different countries. Those trials were published between 2005 and 2022. Sleep Improvement Light therapy led to significant improvements in several sleep measures. It notably enhanced sleep efficiency, increased interdaily stability, and reduced intradaily variability, all of which are indicators of better sleep quality. Light therapy was associated with a reduction in agitation, depression, and caregiver burden among individuals with Alzheimer’s disease. A significant advantage over usual care was shown in reducing the severity of psychobehavioral symptoms, as assessed...

Los no fumadores engordan menos

Un nuevo estudio relaciona el tabaquismo con la ganancia de peso, y concluye que las personas fumadoras activas, no sólo las que lo dejan, engordan más que las no fumadoras. Después de cuatro años de análisis en la Universidad de Navarra, las personas que menos engordaron fueron las que nunca habían fumado.

Lacticaseibacillus rhamnosus may help in periodontal disease

A new study explores how a specific probiotic, Lacticaseibacillus rhamnosus GG (LGG), might help improve the regeneration of bones in the gums affected by periodontal disease, especially in the presence of high cholesterol levels (hyperlipidemia).  Periodontal disease can lead to the loss of bone in the jaw, making it challenging for the bone to regenerate. The researchers used a rat model with conditions mimicking periodontal disease, high cholesterol, and a defect in the gums. The rats were given LGG for six weeks, and then various measurements were taken after sacrificing the rats to understand the effects. They found that the bone density, volume, and thickness in the affected area increased after the rats were given LGG.  Interestingly, these improvements were not due to direct effects on the oral bacteria but were linked to changes in the gut microbiota.  When fecal matter containing the altered gut bacteria from LGG-treated rats was transplanted into other rats, si...